CH1272195H1 - - Google Patents

Info

Publication number
CH1272195H1
CH1272195H1 CH01917289T CH01917289T CH1272195H1 CH 1272195 H1 CH1272195 H1 CH 1272195H1 CH 01917289 T CH01917289 T CH 01917289T CH 01917289 T CH01917289 T CH 01917289T CH 1272195 H1 CH1272195 H1 CH 1272195H1
Authority
CH
Switzerland
Prior art keywords
serm
fulvestrant
patients
treated
previously
Prior art date
Application number
CH01917289T
Other languages
German (de)
English (en)
Inventor
Thurlimann Beat
Original Assignee
Astrazeneca Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CH1272195(H1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ag filed Critical Astrazeneca Ag
Publication of CH1272195H1 publication Critical patent/CH1272195H1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CH01917289T 2000-04-05 2001-04-02 CH1272195H1 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008172.9A GB0008172D0 (en) 2000-04-05 2000-04-05 Therapy

Publications (1)

Publication Number Publication Date
CH1272195H1 true CH1272195H1 (enExample) 2019-10-15

Family

ID=9889101

Family Applications (1)

Application Number Title Priority Date Filing Date
CH01917289T CH1272195H1 (enExample) 2000-04-05 2001-04-02

Country Status (28)

Country Link
US (2) US20030158166A1 (enExample)
EP (2) EP1586323A1 (enExample)
JP (1) JP2003528919A (enExample)
KR (1) KR100757764B1 (enExample)
CN (1) CN1431905A (enExample)
AT (1) ATE306270T1 (enExample)
AU (2) AU2001244372B2 (enExample)
BR (1) BR0109789A (enExample)
CA (1) CA2403608A1 (enExample)
CH (1) CH1272195H1 (enExample)
CZ (1) CZ303096B6 (enExample)
DE (1) DE60113975T2 (enExample)
DK (1) DK1272195T3 (enExample)
EE (1) EE05026B1 (enExample)
ES (1) ES2248300T3 (enExample)
GB (1) GB0008172D0 (enExample)
HU (1) HU230064B1 (enExample)
IL (2) IL151932A0 (enExample)
IS (1) IS2869B (enExample)
MX (1) MXPA02009744A (enExample)
NO (1) NO329949B1 (enExample)
NZ (1) NZ539603A (enExample)
PL (1) PL201175B1 (enExample)
RU (1) RU2265438C2 (enExample)
SK (1) SK287779B6 (enExample)
UA (1) UA80388C2 (enExample)
WO (1) WO2001074366A1 (enExample)
ZA (1) ZA200207538B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004102393A (ru) * 2001-07-07 2005-03-27 Астразенека Аб (Se) Фармацевтическая композиция для внутримышечного введения фульвестранта
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
US8324194B2 (en) * 2005-11-22 2012-12-04 Incyte Corporation Combination therapy for the treatment of cancer
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
SG194735A1 (en) * 2011-05-09 2013-12-30 Univ Virginia Patent Found Compositions and methods for treating cancer
ES2708302T3 (es) 2011-05-20 2019-04-09 Capital Business Y Gestion De Finanzas S L Composición farmacéutica
WO2015106094A1 (en) * 2014-01-10 2015-07-16 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
KR20200052349A (ko) 2017-09-11 2020-05-14 아토사 테라퓨틱스, 인크. 엔독시펜을 제조 및 사용하는 방법
US20210253626A1 (en) * 2018-05-24 2021-08-19 Kashiv Biosciences, Llc Prodrugs of fulvestrant
KR20220042352A (ko) 2019-07-03 2022-04-05 아토사 테라퓨틱스, 인크. 엔독시펜의 서방성 조성물
EP4110344A4 (en) * 2020-02-29 2024-03-13 The University Of Vermont USE OF THYROMIMETICS TO TREAT CANCER

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number Publication date
BR0109789A (pt) 2003-01-21
PL201175B1 (pl) 2009-03-31
EP1272195B1 (en) 2005-10-12
NO20024735L (no) 2002-11-27
CA2403608A1 (en) 2001-10-11
US20110183949A1 (en) 2011-07-28
HUP0300339A3 (en) 2009-01-28
ATE306270T1 (de) 2005-10-15
DE60113975D1 (de) 2006-02-23
DK1272195T3 (da) 2006-01-16
GB0008172D0 (en) 2000-05-24
EE05026B1 (et) 2008-06-16
CN1431905A (zh) 2003-07-23
JP2003528919A (ja) 2003-09-30
HU230064B1 (hu) 2015-06-29
CZ303096B6 (cs) 2012-04-04
EP1272195A1 (en) 2003-01-08
IS6576A (is) 2002-10-01
IS2869B (is) 2014-03-15
NO20024735D0 (no) 2002-10-02
RU2265438C2 (ru) 2005-12-10
ES2248300T3 (es) 2006-03-16
ZA200207538B (en) 2003-12-19
IL151932A (en) 2007-07-04
WO2001074366A1 (en) 2001-10-11
PL357936A1 (en) 2004-08-09
MXPA02009744A (es) 2004-02-26
US20030158166A1 (en) 2003-08-21
KR20030007501A (ko) 2003-01-23
UA80388C2 (en) 2007-09-25
NZ539603A (en) 2008-02-29
SK14292002A3 (sk) 2003-08-05
AU4437201A (en) 2001-10-15
AU2001244372B2 (en) 2006-02-16
DE60113975T2 (de) 2006-06-22
EE200200574A (et) 2004-04-15
HK1051498A1 (en) 2003-08-08
NO329949B1 (no) 2011-01-31
SK287779B6 (sk) 2011-09-05
IL151932A0 (en) 2003-04-10
KR100757764B1 (ko) 2007-09-12
CZ20023309A3 (cs) 2003-02-12
HUP0300339A2 (hu) 2003-06-28
EP1586323A1 (en) 2005-10-19

Similar Documents

Publication Publication Date Title
HUS1500001I1 (hu) ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére
IL177597A0 (en) A kit and an apparatus for treating a patients skin
CH1272195H1 (enExample)
AU6147401A (en) Compositions and methods for the treatment of cancer
ATE430570T1 (de) Synergistische kombinationstherapie zur krebsbehandlung
EP1355563A4 (en) METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
MY138883A (en) Use of asiatic acid for treatment of cencer
EP1077704A4 (en) COMBINATION THERAPY FOR TREATING DEPRESSION
EP1383573A4 (en) METHOD AND DEVICE FOR THE TREATMENT OF ANGRYED TISSUE
HUP0500424A3 (en) Combination therapy for the treatment of cancer
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
EP1320402A4 (en) DEVICE FOR TREATING HEMORRHOIDS AND FOR PROSTATE MASSAGE
IL145397A0 (en) Compositions and methods for treatment of cancer
PL368035A1 (en) Compositions and methods for the treatment of cancer
HUP0301123A3 (en) Use of exemestane for treatment of hormone-dependent breast cancer
AU2003250912A8 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
PL354111A1 (en) Combined therapy for treating the both depression and anxiety
AU2001268762A1 (en) Treatment and therapy apparatus
SI1272195T1 (sl) Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk
UA28113C2 (uk) Спосіб експрес-тестування ефективності реабілітації здоров'я людини
GB0115943D0 (en) Treatment and diagosis of cancer